Asparaginases are part of well-established multi-agent chemotherapeutic regimens in pediatric and adult patients with acute lymphoblastic leukemia (ALL), and emerging evidence has demonstrated their anti-leukemic activity in AML [5,6,7]. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.